Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Oehler VG"" wg kryterium: Autor


Tytuł:
Discovery of U2AF1 neoantigens in myeloid neoplasms.
Autorzy:
Biernacki MA; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA .; Department of Medicine, University of Washington, Seattle, Washington, USA.
Lok J; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Black RG; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Foster KA; Department of Immunology, University of Washington, Seattle, Washington, USA.
Cummings C; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Woodward KB; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Monahan T; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Oehler VG; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Stirewalt DL; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Wu D; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Rongvaux A; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Deeg HJ; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.
Bleakley M; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Dec 12; Vol. 11 (12). Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Myelodysplastic Syndromes*/genetics
Myelodysplastic Syndromes*/therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Leukemia, Myeloid, Acute*/metabolism
Humans ; Mice ; Animals ; CD8-Positive T-Lymphocytes ; Splicing Factor U2AF/genetics ; Splicing Factor U2AF/metabolism ; Antigens, Neoplasm ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; Epitopes/metabolism
Czasopismo naukowe
Tytuł:
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Autorzy:
Zarling LC; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.
Stevenson PA; Clinical Statistics Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Soma LA; Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Martino CH; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Percival MM; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Halpern AB; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Ghiuzeli CM; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Becker PS; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Oehler VG; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Cooper JP; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Orozco JJ; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Hendrie PC; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Walter RB; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Estey EH; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Cassaday RD; Department of Medicine, University of Washington, Seattle, Washington, DC, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2023 Dec; Vol. 111 (6), pp. 863-871. Date of Electronic Publication: 2023 Sep 05.
Typ publikacji:
Journal Article
MeSH Terms:
Doxorubicin*/therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/etiology
Adult ; Humans ; Retrospective Studies ; Cyclophosphamide/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Vincristine/therapeutic use ; Dexamethasone
SCR Protocol:
EPOCH protocol
Czasopismo naukowe
Tytuł:
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Autorzy:
Winn AN; Department of Health Systems, Outcomes and Policy, School of Pharmacy, University of Illinois at Chicago.
Atallah E; Department of Medicine, Medical College of Wisconsin, Milwaukee.
Cortes J; Georgia Cancer Center, Augusta University Medical Center, Augusta.
Deininger MWN; Department of Medicine, Medical College of Wisconsin, Milwaukee.
Kota V; Georgia Cancer Center, Augusta University Medical Center, Augusta.
Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, Illinois.
Moore JO; Duke University School of Medicine, Durham, North Carolina.
Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, New York.
Oehler VG; Fred Hutchinson Cancer Research Center, Seattle, Washington.
Pinilla-Ibarz J; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Radich JP; Fred Hutchinson Cancer Research Center, Seattle, Washington.
Shah NP; Department of Medicine, University of California at San Francisco.
Thompson JE; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Flynn KE; Department of Medicine, Medical College of Wisconsin, Milwaukee.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2023 Dec 01; Vol. 6 (12), pp. e2347950. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article
MeSH Terms:
Tyrosine Kinase Inhibitors*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Adult ; Male ; Humans ; Female ; Health Care Costs ; Income ; Patients ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Autorzy:
Flynn KE; Medical College of Wisconsin, Milwaukee, WI. .
Atallah E; Medical College of Wisconsin, Milwaukee, WI.
Lin L; Duke University School of Medicine, Durham, NC.
Shah NP; University of California at San Francisco, San Francisco, CA.
Silver RT; Weill Cornell Medicine, New York, NY.
Larson RA; University of Chicago, Chicago, IL.
Panilla-Ibarz J; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Thompson JE; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Oehler VG; Fred Hutchinson Cancer Research Center, Seattle, WA.
Radich JP; Fred Hutchinson Cancer Research Center, Seattle, WA.
Kota V; Georgia Cancer Center at Augusta University, Augusta, GA.
Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, NY.
Schiffer CA; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI.
Cortes J; Georgia Cancer Center at Augusta University, Augusta, GA.
Weinfurt KP; Duke University School of Medicine, Durham, NC.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2022 Nov 01; Vol. 107 (11), pp. 2641-2649. Date of Electronic Publication: 2022 Nov 01.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Musculoskeletal Pain*/chemically induced
Musculoskeletal Pain*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Physicians*
Humans ; Prospective Studies ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
Autorzy:
Godwin CD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Rodríguez-Arbolí E; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Appelbaum JS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Percival MM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Hendrie PC; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Keel SB; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Abkowitz JL; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Cooper JP; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Estey EH; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA 98195, USA.; Department of Epidemiology, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jun 14; Vol. 14 (12). Date of Electronic Publication: 2022 Jun 14.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Autorzy:
Garcia KA; Department of Medicine, University of Washington, Seattle, Washington.
Cherian S; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
Stevenson PA; Clinical Statistics Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Biostatistics, University of Washington, Seattle, Washington.
Martino CH; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.
Shustov AR; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Becker PS; Department of Medicine, University of Washington, Seattle, Washington.; Department of Medicine, University of California Irvine, Irvine, California.
Percival MM; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Oehler VG; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Halpern AB; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Walter RB; Department of Medicine, University of Washington, Seattle, Washington.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Orozco JJ; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Keel SB; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.
Estey EH; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Cassaday RD; Department of Medicine, University of Washington, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Pokaż więcej
Źródło:
Cancer [Cancer] 2022 Apr 01; Vol. 128 (7), pp. 1411-1417. Date of Electronic Publication: 2021 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Central Nervous System ; Cytarabine ; Flow Cytometry ; Humans ; Recurrence
Czasopismo naukowe
Tytuł:
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
Autorzy:
Palmieri R; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.
Buckley SA; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.
Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Percival MM; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Scott BL; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Hendrie PC; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA.
Becker PS; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1728-1731. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji:
Clinical Trial, Phase I; Letter; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms:
Cladribine*/therapeutic use
Cytarabine*/therapeutic use
Decitabine*/therapeutic use
Granulocyte Colony-Stimulating Factor*/therapeutic use
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Mitoxantrone*/therapeutic use
Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Treatment Outcome
Raport
Tytuł:
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis.
Autorzy:
Godavarthy PS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.
Kumar R; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.
Herkt SC; Institute for Transfusion Medicine DRK- Blutspendedienst Baden-Württemberg - Hessen, Frankfurt am Main, Germany.
Pereira RS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.
Hayduk N; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.
Weissenberger ES; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.
Aggoune D; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany.
Manavski Y; Institute of Cardiovascular Regeneration, Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
Lucas T; Institute of Cardiovascular Regeneration, Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
Pan KT; Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.
Voutsinas JM; Fred Hutchinson Cancer Research Center, Clinical Research Division, Biostatistics, Seattle, WA, USA.
Wu Q; Fred Hutchinson Cancer Research Center, Clinical Research Division, Biostatistics, Seattle, WA, USA.
Müller MC; Institute for Hematology and Oncology, Mannheim, Germany.
Saussele S; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Oellerich T; Department of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt am Main, Germany.; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.
Oehler VG; Fred Hutchinson Cancer Research Center, Clinical Research Division, Division of Hematology, University of Washington Medical Center, Seattle, WA, USA.
Lausen J; Institute for Transfusion Medicine DRK- Blutspendedienst Baden-Württemberg - Hessen, Frankfurt am Main, Germany.
Krause DS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany .; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.; Faculty of Medicine, Johann Wolfgang Goethe University, Frankfurt.; Frankfurt Cancer Institute, Frankfurt, Germany.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2020 Jan; Vol. 105 (1), pp. 136-147. Date of Electronic Publication: 2019 Apr 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Fusion Proteins, bcr-abl*/genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics
Animals ; Bone Marrow ; E-Selectin/genetics ; Endothelial Cells ; Mice ; Proto-Oncogene Mas ; T-Cell Acute Lymphocytic Leukemia Protein 1
Czasopismo naukowe
Tytuł:
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Autorzy:
Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington.
Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center.
Huebner EM; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Scott BL; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Medical Oncology, University of Washington.
Hendrie PC; Department of Medicine, Division of Hematology, University of Washington.; Seattle Cancer Care Alliance.
Percival MM; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington.
Becker PS; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington.
Smith HA; Seattle Cancer Care Alliance.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington.
Orozco JJ; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington.
Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington.
Gardner KM; Department of Medicine, Division of Hematology, University of Washington.
Chen TL; Deparment of Pharmacy Services, University of Washington.
Buckley SA; Hematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center.
Orlowski KF; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.
Anwar A; Hematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center.
Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington.; Department of Medicine, Division of Hematology, University of Washington.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington .; Department of Medicine, Division of Hematology, University of Washington.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2019 Apr; Vol. 104 (4), pp. e143-e146. Date of Electronic Publication: 2018 Nov 08.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Hematologic Neoplasms/*drug therapy
Hematologic Neoplasms/*mortality
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*mortality
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cladribine/administration & dosage ; Cladribine/adverse effects ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/adverse effects ; Hematologic Neoplasms/pathology ; Humans ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Mitoxantrone/administration & dosage ; Mitoxantrone/adverse effects ; Survival Rate
Raport
Tytuł:
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Autorzy:
Cortes JE; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Douglas Smith B; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Wang ES; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Merchant A; Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Oehler VG; Fred Hutchinson Cancer Research Center, Seattle, Washington.
Arellano M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
DeAngelo DJ; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Pollyea DA; Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.
Sekeres MA; Leukemia Program, Cleveland Clinic, Cleveland, Ohio.
Robak T; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Ma WW; Pfizer Oncology, New York, New York.
Zeremski M; Pfizer Oncology, New York, New York.
Naveed Shaik M; Pfizer Oncology, New York, New York.
Douglas Laird A; Pfizer Oncology, New York, New York.
O'Connell A; Pfizer Oncology, New York, New York.
Chan G; Pfizer Oncology, New York, New York.
Schroeder MA; Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2018 Nov; Vol. 93 (11), pp. 1301-1310. Date of Electronic Publication: 2018 Sep 09.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Benzimidazoles/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Myelodysplastic Syndromes/*drug therapy
Phenylurea Compounds/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Consolidation Chemotherapy/methods ; Cytarabine/administration & dosage ; Daunorubicin/administration & dosage ; Female ; Humans ; Leukemia, Myeloid, Acute/complications ; Maintenance Chemotherapy/methods ; Male ; Middle Aged ; Myelodysplastic Syndromes/complications ; Remission Induction/methods ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Autorzy:
Atallah E; Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA.
Schiffer CA; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Weinfurt KP; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Zhang MJ; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.
Radich JP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Pinilla-Ibarz J; Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Deininger MWN; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA.
Lin L; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA.
Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Moore JO; Duke Cancer Institute, Durham, NC, USA.
Ritchie EK; Weill Medical College of Cornell University, New York, NY, USA.
Shah NP; Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Silver RT; Weill Medical College of Cornell University, New York, NY, USA.
Wadleigh M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Cortes J; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thompson J; Roswell Park Cancer Institute, Buffalo, NY, USA.
Guhl J; Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Horowitz MM; Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA.
Flynn KE; Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Apr 02; Vol. 18 (1), pp. 359. Date of Electronic Publication: 2018 Apr 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Clinical Protocols*
Quality of Life*
Watchful Waiting*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*psychology
Antineoplastic Agents/therapeutic use ; Fusion Proteins, bcr-abl/genetics ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Longitudinal Studies ; Molecular Targeted Therapy ; Patient Reported Outcome Measures ; Protein Kinase Inhibitors/therapeutic use ; Recurrence ; Research Design
Czasopismo naukowe
Tytuł:
A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
Autorzy:
Lee SI; Paul G. Allen School of Computer Science and Engineering, University of Washington, 185 E Stevens Way NE, Seattle, WA, 98195, USA. .; Department of Genome Sciences, University of Washington, 3720 15th Ave NE, Seattle, WA, 98195, USA. .; Center for Cancer Innovation, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA. .
Celik S; Paul G. Allen School of Computer Science and Engineering, University of Washington, 185 E Stevens Way NE, Seattle, WA, 98195, USA.
Logsdon BA; Sage Bionetworks, 1100 Fairview Ave N, Seattle, WA, 98109, USA.
Lundberg SM; Paul G. Allen School of Computer Science and Engineering, University of Washington, 185 E Stevens Way NE, Seattle, WA, 98195, USA.
Martins TJ; Quellos High Throughput Screening Core, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Miller CP; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Chien S; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Dai J; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Saxena A; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Blau CA; Center for Cancer Innovation, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Becker PS; Center for Cancer Innovation, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.; Division of Hematology, Department of Medicine and Institute for Stem Cell and Regenerative Medicine, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2018 Jan 03; Vol. 9 (1), pp. 42. Date of Electronic Publication: 2018 Jan 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Machine Learning*
DNA Helicases/*genetics
Drug Resistance, Neoplasm/*genetics
Leukemia, Myeloid, Acute/*genetics
Nuclear Proteins/*genetics
Precision Medicine/*methods
Transcription Factors/*genetics
Algorithms ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/metabolism ; Cell Line ; Datasets as Topic ; Etoposide/pharmacology ; Etoposide/therapeutic use ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Topoisomerase II Inhibitors/pharmacology ; Topoisomerase II Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Autorzy:
Ramamurthy R; University of Washington School of Medicine, Seattle, Washington.
Hughes M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Children's Hospital, Seattle, Washington.
Morris V; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Bolouri H; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Gerbing RB; Children's Oncology Group, Monrovia, California.
Wang YC; Children's Oncology Group, Monrovia, California.
Loken MR; Hematologics, Inc, Seattle, Washington.
Raimondi SC; Children's Oncology Group, Monrovia, California.; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Hirsch BA; Children's Oncology Group, Monrovia, California.; Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota.
Gamis AS; Children's Oncology Group, Monrovia, California.; Children's Mercy Hospitals & Clinics, Kansas City, Missiouri.
Oehler VG; University of Washington School of Medicine, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Alonzo TA; Keck School of Medical Department of Preventive Medicine, University of Southern California, Los Angeles, California.
Meshinchi S; University of Washington School of Medicine, Seattle, Washington. .; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. .; Seattle Children's Hospital, Seattle, Washington. .; Children's Oncology Group, Monrovia, California. .
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2016 Dec; Vol. 63 (12), pp. 2096-2103. Date of Electronic Publication: 2016 Aug 11.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute/*genetics
MicroRNAs/*analysis
Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Leukemia, Myeloid, Acute/mortality ; Male ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł:
CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.
Autorzy:
Bajaj J; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Konuma T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Lytle NK; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Kwon HY; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Ablack JN; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Cantor JM; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Rizzieri D; Division of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Chuah C; Department of Haematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore 169857, Singapore.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center, WA 98109, USA.
Broome EH; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Ball ED; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, Blood and Marrow Transplantation Division, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
van der Horst EH; Igenica Biotherapeutics Inc., Burlingame, CA 94010, USA.
Ginsberg MH; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address: .
Reya T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2016 Nov 14; Vol. 30 (5), pp. 792-805. Date of Electronic Publication: 2016 Oct 27.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Antibodies/*administration & dosage
Fusion Regulatory Protein-1/*genetics
Leukemia, Myeloid, Acute/*drug therapy
Neoplastic Stem Cells/*pathology
Animals ; Antibodies/pharmacology ; Cell Adhesion ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Fusion Regulatory Protein-1/antagonists & inhibitors ; Gene Knockout Techniques ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Mice ; Neoplasm Transplantation
Czasopismo naukowe
Tytuł:
Small, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: Does this finding indicate an accelerated course?
Autorzy:
Soma L; Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, 98109. .
Oehler VG; Department of Hematology-Oncology, University of Washington Medical Center, Seattle, Washington, 98109.
Ding C; Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, 98109.
Cherian S; Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, 98109.
Pokaż więcej
Źródło:
Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2016 Sep; Vol. 90 (5), pp. 440-8. Date of Electronic Publication: 2016 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Blast Crisis/*pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis
Precursor Cells, B-Lymphoid/*immunology
Precursor Cells, B-Lymphoid/*pathology
Adolescent ; Adult ; Antigens, CD34/immunology ; Female ; Flow Cytometry/methods ; Humans ; Immunohistochemistry/methods ; Immunophenotyping/methods ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł:
Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.
Autorzy:
Brehme M; Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, Germany.
Koschmieder S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Montazeri M; Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, Germany.
Copland M; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow G12 0ZD, United Kingdom.
Oehler VG; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Radich JP; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Brümmendorf TH; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
Schuppert A; Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52062 Aachen, Germany.; Aachen Institute for Advanced Study in Computational Engineering Science (AICES), RWTH Aachen University, 52062 Aachen, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2016 Apr 06; Vol. 6, pp. 24057. Date of Electronic Publication: 2016 Apr 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Disease Progression*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*pathology
Antigens, CD34/metabolism ; Biomarkers, Tumor/metabolism ; Biopsy ; Cohort Studies ; Drug Resistance, Neoplasm ; Entropy ; Gene Expression Profiling ; Gene Expression Regulation, Leukemic ; Genomics ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/classification ; Models, Biological ; Population Dynamics ; Prognosis ; Risk Assessment ; Stem Cells/cytology
Czasopismo naukowe
Tytuł:
Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.
Autorzy:
Kwon HY; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Soonchunhyang Institute of Medi-bio Science, Soonchunhyang University, Asan-si, Chungcheongnamdo 336-745, South Korea.
Bajaj J; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.
Ito T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.
Blevins A; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.
Konuma T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.
Weeks J; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.
Lytle NK; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.
Koechlein CS; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.
Rizzieri D; Division of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Chuah C; Department of Haematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore 169857.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center, WA 98109, USA.
Sasik R; Center for Computational Biology and Bioinformatics, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Hardiman G; Computational Science Research Center and Biomedical Informatics Research Center, San Diego State University, San Diego, CA 92182, USA.; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Reya T; Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92093, USA.; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.
Pokaż więcej
Źródło:
Cell stem cell [Cell Stem Cell] 2015 Aug 06; Vol. 17 (2), pp. 152-164. Date of Electronic Publication: 2015 Jul 23.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinogenesis/*pathology
Leukemia, Myeloid, Acute/*pathology
Tetraspanins/*metabolism
Animals ; Carcinogenesis/drug effects ; Carcinogenesis/metabolism ; Cell Movement/drug effects ; Chemokine CXCL12/pharmacology ; Genome ; Histone-Lysine N-Methyltransferase/metabolism ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Leukemia, Myeloid, Acute/genetics ; Mice, Inbred C57BL ; Mice, Knockout ; Myeloid-Lymphoid Leukemia Protein/metabolism ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/pathology ; Tetraspanins/deficiency ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
Autorzy:
Huang JC; 1] Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA [2] Division of Gerontology & Geriatric Medicine, University of Washington, Seattle, WA, USA.
Basu SK; Section of Hematology & Oncology, West Virginia University School of Medicine, Morgantown, WV, USA.
Zhao X; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Chien S; Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA.
Fang M; 1] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pathology and Laboratory Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA.
Oehler VG; 1] Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA [2] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Appelbaum FR; 1] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
Becker PS; 1] Division of Hematology, Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA [2] Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2015 Apr 10; Vol. 5, pp. e302. Date of Electronic Publication: 2015 Apr 10.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Chromosome Aberrations*
Mesenchymal Stem Cells*
Bone Marrow/*pathology
Leukemia, Myeloid, Acute/*genetics
Tumor Microenvironment/*genetics
Adult ; Aged ; Animals ; Cell Differentiation/genetics ; Cell Proliferation/genetics ; Cytogenetic Analysis ; Female ; Gene Expression Regulation, Leukemic ; Humans ; Leukemia, Myeloid, Acute/pathology ; Male ; Mice ; Middle Aged ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Protein Glutamine gamma Glutamyltransferase 2 ; Transcriptome
Czasopismo naukowe
Tytuł:
Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia.
Autorzy:
Zimdahl B; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3] Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA. [4].
Ito T; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3].
Blevins A; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.
Bajaj J; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.
Konuma T; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.
Weeks J; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.
Koechlein CS; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.
Kwon HY; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.
Arami O; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA.
Rizzieri D; Division of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Broome HE; 1] Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, California, USA.
Chuah C; 1] Department of Haematology, Singapore General Hospital, Singapore. [2] Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School, Singapore.
Oehler VG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Sasik R; Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA.
Hardiman G; 1] Department of Medicine, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Computational Science Research Center and Biomedical Informatics Research Center, San Diego State University, San Diego, California, USA.
Reya T; 1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3] Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA. [4] Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, California, USA.
Pokaż więcej
Źródło:
Nature genetics [Nat Genet] 2014 Mar; Vol. 46 (3), pp. 245-52. Date of Electronic Publication: 2014 Feb 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
1-Alkyl-2-acetylglycerophosphocholine Esterase/*physiology
Hematopoietic Stem Cells/*cytology
Hematopoietic Stem Cells/*physiology
Leukemia, Myeloid/*pathology
Leukemia, Myeloid/*physiopathology
Microtubule-Associated Proteins/*physiology
1-Alkyl-2-acetylglycerophosphocholine Esterase/antagonists & inhibitors ; 1-Alkyl-2-acetylglycerophosphocholine Esterase/deficiency ; 1-Alkyl-2-acetylglycerophosphocholine Esterase/genetics ; Animals ; Carcinogenesis ; Cell Division ; Cell Line, Tumor ; Female ; Hematopoiesis ; Humans ; K562 Cells ; Leukemia, Myeloid/genetics ; Male ; Mice ; Mice, Knockout ; Mice, Transgenic ; Microtubule-Associated Proteins/antagonists & inhibitors ; Microtubule-Associated Proteins/deficiency ; Microtubule-Associated Proteins/genetics ; Phenotype ; Pregnancy ; Spindle Apparatus/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies